Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Hematologic Malignancy Reports|January 7, 2014
Immunology and immunotherapy of chronic myeloid leukemiaMette Ilander, Can Hekim, Satu Mustjoki
Methods in Molecular Biology (Clifton, N.J.)|October 23, 2013
Evaluation of peptides as protease inhibitors and stimulatorsHannu Koistinen, Can Hekim, Ping Wu, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|January 18, 2005
Hyperprolactinaemia does not always mean 'hyperprolactinaemia'!Altay Gezer, Turgay Atasü, Can Hekim, et al.
The Prostate|November 26, 2009
Complex formation between human prostate-specific antigen and protease inhibitors in mouse plasmaCan Hekim, Tero Riipi, Lei Zhu, et al.
Biological Chemistry|February 26, 2010
Identification of IGFBP-3 fragments generated by KLK2 and prevention of fragmentation by KLK2-inhibiting peptidesCan Hekim, Tero Riipi, Janne Weisell, et al.
The Journal of Biological Chemistry|March 11, 2006
Novel peptide inhibitors of human kallikrein 2Can Hekim, Jari Leinonen, Ale Närvänen, et al.
Biological Chemistry|July 17, 2008
Development of peptides specifically modulating the activity of KLK2 and KLK3Hannu Koistinen, Ale Närvänen, Miikka Pakkala, et al.
Plos One|September 20, 2014
Proteolytic activity of prostate-specific antigen (PSA) towards protein substrates and effect of peptides stimulating PSA activityJohanna M Mattsson, Suvi Ravela, Can Hekim, et al.
Blood|March 11, 2022
Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemiaSean I Tracy, Hrishi Venkatesh, Can Hekim, et al.
Amino Acids|December 8, 2009
Mimetics of the disulfide bridge between the N- and C-terminal cysteines of the KLK3-stimulating peptide B-2Miikka Pakkala, Janne Weisell, Can Hekim, et al.
Pageof 2